Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Mar 21, 2021 11:32am
175 Views
Post# 32846799

RE:RE:New poster on liver inflammation at Endo

RE:RE:New poster on liver inflammation at EndoI believe there is a note at the end of the link in the press release where the folks that run the ENDO conference require companies to not divulge anything about their session until 11AM the day t he conferencec started. I have to believe they could have at least said they would be presenting a paper there earlier, but maybe even that is not allowed. 

ANALIAS00 wrote: Light question ...

Who knew about the "Endocrine Societys annual meeting, ENDO 2021" ?

Why important enought to send a PR after that meeting and not enought to send a PR announcing that they would be attending that meeting ?

Is it just normal in the industry or part of a strategy ?
jfm1330 wrote: Strange to publish that on a friday night.


https://www.abstractsonline.com/pp8/#!/9188/presentation/2240



https://www.theratech.com/theratechnologies-announces-new-data-demonstrating-tesamorelins-positive-effect-on-immune-response-linked-to-liver-inflammation/




<< Previous
Bullboard Posts
Next >>